DRG2

Summary

DRG2 (developmentally regulated GTP binding protein 2, HGNC:3030) is a protein-coding gene on chromosome 17p11.2, encoding Developmentally-regulated GTP-binding protein 2 (P55039). Catalyzes the conversion of GTP to GDP through hydrolysis of the gamma-phosphate bond in GTP.

This gene encodes a GTP-binding protein known to function in the regulation of cell growth and differentiation. Read-through transcripts containing this gene and a downstream gene have been identified, but they are not thought to encode a fusion protein. This gene is located within the Smith-Magenis syndrome region on chromosome 17.

Source: NCBI Gene 1819 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 65 total — 1 pathogenic
• MANE Select transcript: NM_001388

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3030
Approved symbol	DRG2
Name	developmentally regulated GTP binding protein 2
Location	17p11.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000108591
Ensembl biotype	protein_coding
OMIM	602986
Entrez	1819

Gene structure

Transcript identifiers

Ensembl transcripts: 34 — 18 protein_coding, 9 retained_intron, 7 nonsense_mediated_decay

ENST00000225729, ENST00000395726, ENST00000467099, ENST00000473213, ENST00000482564, ENST00000496428, ENST00000497744, ENST00000577450, ENST00000577771, ENST00000578173, ENST00000578767, ENST00000579224, ENST00000579601, ENST00000580055, ENST00000580929, ENST00000582314, ENST00000582419, ENST00000582528, ENST00000583162, ENST00000583355, ENST00000584212, ENST00000864160, ENST00000864161, ENST00000864162, ENST00000864163, ENST00000864164, ENST00000864165, ENST00000864166, ENST00000864167, ENST00000864168, ENST00000925712, ENST00000925714, ENST00000968692, ENST00000968693

RefSeq mRNA: 2 — MANE Select: NM_001388 NM_001330144, NM_001388

CCDS: CCDS11191, CCDS82082

Canonical transcript exons

ENST00000225729 — 13 exons

Exon	Start	End
ENSE00002371187	18107154	18107969
ENSE00002701416	18087948	18088087
ENSE00003494670	18099017	18099077
ENSE00003499494	18101921	18101997
ENSE00003507447	18103801	18103889
ENSE00003576648	18101493	18101590
ENSE00003593531	18100569	18100659
ENSE00003596392	18104623	18104681
ENSE00003628935	18106433	18106486
ENSE00003648761	18099633	18099723
ENSE00003650739	18093813	18093973
ENSE00003662247	18098270	18098359
ENSE00003669408	18100363	18100435

Expression profiles

Bgee: expression breadth ubiquitous, 251 present calls, max score 93.30.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 27.3530 / max 191.2047, expressed in 1802 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
159782	25.9208	1792
159781	0.9038	617
159783	0.5284	136

Top tissues by expression

281 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
granulocyte	CL:0000094	93.30	gold quality
right lobe of liver	UBERON:0001114	93.11	gold quality
adenohypophysis	UBERON:0002196	92.70	gold quality
apex of heart	UBERON:0002098	92.02	gold quality
pituitary gland	UBERON:0000007	91.87	gold quality
type B pancreatic cell	CL:0000169	91.84	gold quality
lower esophagus mucosa	UBERON:0035834	91.81	gold quality
body of uterus	UBERON:0009853	91.79	gold quality
gastrocnemius	UBERON:0001388	91.70	gold quality
right ovary	UBERON:0002118	91.53	gold quality
right lobe of thyroid gland	UBERON:0001119	91.49	gold quality
olfactory bulb	UBERON:0002264	91.47	gold quality
left ovary	UBERON:0002119	91.44	gold quality
endocervix	UBERON:0000458	91.38	gold quality
muscle of leg	UBERON:0001383	91.24	gold quality
left lobe of thyroid gland	UBERON:0001120	91.12	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	90.89	gold quality
skin of leg	UBERON:0001511	90.83	gold quality
lower esophagus	UBERON:0013473	90.82	gold quality
lower esophagus muscularis layer	UBERON:0035833	90.82	gold quality
left uterine tube	UBERON:0001303	90.73	gold quality
left adrenal gland cortex	UBERON:0035825	90.73	gold quality
right uterine tube	UBERON:0001302	90.69	gold quality
metanephros cortex	UBERON:0010533	90.68	gold quality
ectocervix	UBERON:0012249	90.66	gold quality
mucosa of stomach	UBERON:0001199	90.58	gold quality
muscle layer of sigmoid colon	UBERON:0035805	90.58	gold quality
hindlimb stylopod muscle	UBERON:0004252	90.56	gold quality
skin of abdomen	UBERON:0001416	90.55	gold quality
left adrenal gland	UBERON:0001234	90.49	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.91
E-CURD-10	no	274.03

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): GLI1, SP1

miRNA regulators (miRDB)

38 targeting DRG2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012
HSA-MIR-6133	100.00	66.48	2064
HSA-MIR-6740-5P	100.00	65.64	932
HSA-MIR-205-3P	99.92	69.92	3165
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-1343-3P	99.89	66.78	1815
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-6794-5P	99.76	66.38	1048
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-7106-5P	99.53	67.47	3574
HSA-MIR-3612	99.45	66.02	1333
HSA-MIR-650	99.45	65.77	1309
HSA-MIR-6722-3P	99.45	67.62	1919
HSA-MIR-3182	99.40	68.15	2454
HSA-MIR-4652-3P	99.33	70.02	2742
HSA-MIR-6852-5P	99.17	66.69	2073
HSA-MIR-6799-5P	99.14	65.72	2093
HSA-MIR-939-3P	98.97	65.07	2347
HSA-MIR-5001-3P	98.91	67.28	1394
HSA-MIR-501-5P	98.77	68.88	1328
HSA-MIR-7155-5P	98.65	66.14	1290
HSA-MIR-4700-5P	98.63	67.43	1915
HSA-MIR-6742-3P	97.95	64.50	1490
HSA-MIR-8089	97.74	66.21	1698

Literature-anchored findings (GeneRIF, showing 13)

• overexpression of DRG2 in Jurkat cells affects genes regulating cell-cycle arrest and apoptosis, and that these molecular changes may be important in the growth or differentiation of cells (PMID:15113831)
• Basal expression level of DRG2 is regulated by the Sp1 transcription factor. (PMID:21296692)
• miR19153p functions as a silencer of apoptosis, which regulates lung cancer apoptosis via targeting DRG2/PBX2. (PMID:26572100)
• Results demonstrate that DRG2 is an endosomal protein and a key regulator of Rab5 deactivation and Tfn recycling. (PMID:26582392)
• Authors observed that knockdown of DRG2 in HeLa cells affected growth in a wound-healing assay, and tumorigenicity in nude mice xenografts. (PMID:27669826)
• Taken together, our data demonstrate that DRG2 acts as a regulator of mitochondrial fission by controlling the expression of Drp1. (PMID:28363867)
• Results show that the SNP (rs2257609 C>T) located in the intron region of SLC5A10 variant does not affect the expression of SLC5A10 mRNA, but alters the mRNA expression and promoter activity of DRG2. It is significantly associated with worse overall and disease-free survival of non-small-cell lung cancer (NSCLC) patients. (PMID:30281872)
• Using immunoprecipitation, authors show that DRG2 interacts with tau, which regulates microtubule polymerization. Collectively, these data demonstrate that DRG2 may aid in affecting microtubule dynamics in HeLa cells. (PMID:30453731)
• Knockdown of DRG2 in HeLa cells treated with epidermal growth factor (EGF) affects microtubule dynamics, perinuclear Golgi stacking, and cell migration. (PMID:31199931)
• DRG2 supports the growth of primary tumors and metastases of melanoma by enhancing VEGF-A expression. (PMID:31693298)
• Developmentally regulated GTP-binding protein 2 levels in prostate cancer cell lines impact docetaxel-induced apoptosis. (PMID:34190439)
• Developmentally regulated GTP-binding protein-2 regulates adipocyte differentiation. (PMID:34520979)
• Developmentally regulated GTPases: structure, function and roles in disease. (PMID:34664086)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	drg2	ENSDARG00000006642
mus_musculus	Drg2	ENSMUSG00000020537
rattus_norvegicus	Drg2	ENSRNOG00000055309
drosophila_melanogaster	CG6195	FBGN0038723
caenorhabditis_elegans		WBGENE00015346

Paralogs (4): MTG2 (ENSG00000101181), GTPBP10 (ENSG00000105793), GTPBP4 (ENSG00000107937), DRG1 (ENSG00000185721)

Protein

Protein identifiers

Developmentally-regulated GTP-binding protein 2 — P55039 (reviewed: P55039)

Alternative names: Translation factor GTPase DRG2

All UniProt accessions (10): P55039, A8MZF9, J3KRL5, J3QKV7, J3QKW7, J3QL90, J3QLF3, J3QQI1, J3QR71, J3QRI9

UniProt curated annotations — full annotation on UniProt →

Function. Catalyzes the conversion of GTP to GDP through hydrolysis of the gamma-phosphate bond in GTP. When hydroxylated at C-3 of ‘Lys-21’ by JMJD7, may bind to RNA and play a role in translation.

Subunit / interactions. Interacts with RWDD1; this interaction confers protection to polyubiquitination and proteolytic degradation. Interacts with JMJD7; this interaction is direct.

Subcellular location. Nucleus. Cytoplasm.

Tissue specificity. Highest levels in skeletal muscle, heart and kidney. Low levels in colon, thymus, spleen, small intestine, lung and Leukocytes.

Post-translational modifications. Hydroxylated (with S stereochemistry) at C-3 of Lys-21 by JMJD7; this modification hinders trypsin-catalyzed proteolysis in vitro. Polyubiquitinated.

Similarity. Belongs to the TRAFAC class OBG-HflX-like GTPase superfamily. OBG GTPase family.

RefSeq proteins (2): NP_001317073, NP_001379* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004095	TGS	Domain
IPR005225	Small_GTP-bd	Domain
IPR006073	GTP-bd	Domain
IPR006074	GTP1-OBG_CS	Conserved_site
IPR012675	Beta-grasp_dom_sf	Homologous_superfamily
IPR012676	TGS-like	Homologous_superfamily
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR031167	G_OBG	Domain
IPR031662	GTP-binding_2	Domain
IPR045001	DRG	Family

Pfam: PF01926, PF02824, PF16897

Catalyzed reactions (Rhea), 1 shown:

• GTP + H2O = GDP + phosphate + H(+) (RHEA:19669)

UniProt features (14 total): binding site 7, domain 2, sequence variant 2, chain 1, modified residue 1, mutagenesis site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P55039-F1	85.40	0.54

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (7): 69–76; 76; 94–98; 96; 115–118; 246–249; 269–271

Post-translational modifications (1): 21

Mutagenesis-validated functional residues (1):

Position	Phenotype
21	impairs jmjd7-mediated hydroxylation and ribonucleic acid binding.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9629569	Protein hydroxylation

MSigDB gene sets: 188 (showing top): GOBP_CYTOPLASMIC_TRANSLATION, HORIUCHI_WTAP_TARGETS_DN, SHEPARD_CRASH_AND_BURN_MUTANT_UP, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GCM_MYCL1, GOBP_TRANSLATION, GCM_PRKCG, GCM_RING1, HOSHIDA_LIVER_CANCER_SUBCLASS_S3, GCM_FCGR2B, GCM_DPF2, MORF_PML, GCM_ATM, MORF_PDPK1, MORF_IKBKG

GO Biological Process (2): cytoplasmic translation (GO:0002181), signal transduction (GO:0007165)

GO Molecular Function (7): RNA binding (GO:0003723), GTPase activity (GO:0003924), GTP binding (GO:0005525), metal ion binding (GO:0046872), nucleotide binding (GO:0000166), protein binding (GO:0005515), hydrolase activity (GO:0016787)

GO Cellular Component (5): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), cytosol (GO:0005829), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
translation	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
nucleic acid binding	1
ribonucleoside triphosphate phosphatase activity	1
guanyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
cation binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
catalytic activity	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

2718 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DRG2	RWDD1	Q9H446	926
DRG2	ZC3H15	Q8WU90	805
DRG2	GCN1	Q92616	615
DRG2	LRRC18	Q8N456	605
DRG2	JMJD7	P0C870	507
DRG2	MAP7	Q14244	476
DRG2	EAPP	Q56P03	472
DRG2	ARFGEF3	Q5TH69	449
DRG2	RPL27A	P46776	445
DRG2	DRC3	Q9H069	432
DRG2	MYO15A	Q9UKN7	419
DRG2	ATPAF2	Q8N5M1	409
DRG2	ZCCHC4	Q9H5U6	409
DRG2	NATD1	Q8N6N6	400
DRG2	MLEC	Q14165	394

IntAct

53 interactions, top by confidence:

A	B	Type	Score
RWDD1	DRG2	psi-mi:“MI:0915”(physical association)	0.900
DRG2	RWDD1	psi-mi:“MI:0915”(physical association)	0.900
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
DRG2	NAB2	psi-mi:“MI:0915”(physical association)	0.560
DRG2	TSSK3	psi-mi:“MI:0915”(physical association)	0.560
JMJD7	DRG2	psi-mi:“MI:0915”(physical association)	0.560
EIF4A3	DRG2	psi-mi:“MI:0915”(physical association)	0.560
DRG2	JPH3	psi-mi:“MI:0915”(physical association)	0.560
DRG2	SPRED1	psi-mi:“MI:0915”(physical association)	0.560
DRG2	HSPA8	psi-mi:“MI:0914”(association)	0.530
nleB1	DRG2	psi-mi:“MI:0915”(physical association)	0.370
DRG2	nleB1	psi-mi:“MI:0915”(physical association)	0.370
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
HSCB	RBP5	psi-mi:“MI:0914”(association)	0.350
MKI67	ARHGAP10	psi-mi:“MI:0914”(association)	0.350
LRRK2		psi-mi:“MI:0914”(association)	0.350
M		psi-mi:“MI:0914”(association)	0.350
KCNE3	PIK3R2	psi-mi:“MI:0914”(association)	0.350
DRG2	MAPK13	psi-mi:“MI:0914”(association)	0.350
TNFRSF1B	MAP3K7	psi-mi:“MI:0914”(association)	0.350
DRG2	DHPS	psi-mi:“MI:0914”(association)	0.350

BioGRID (105): RWDD1 (Two-hybrid), HSPA8 (Affinity Capture-MS), RWDD1 (Affinity Capture-MS), RWDD1 (Two-hybrid), DDX55 (Co-fractionation), RWDD1 (Co-fractionation), DRG2 (Proximity Label-MS), DRG2 (Proximity Label-MS), DRG2 (Affinity Capture-MS), CUL1 (Affinity Capture-Western), SKP1 (Affinity Capture-Western), RWDD1 (Affinity Capture-MS), HSPA8 (Affinity Capture-MS), DRG2 (Affinity Capture-MS), DRG2 (Proximity Label-MS)

ESM2 similar proteins: A0A384E139, A1RRV1, A1RVI0, A4YF02, B5YA17, C0QTG9, C3MKR6, C3MRI1, C3MUB4, C3MY77, C3MZK6, C3N1A2, C3N7M8, C3N992, C3NFU5, C3NMW1, C4KIT6, C4KKU5, E3GZ90, O27449, O29758, O58452, O67004, P32235, P39466, P55039, P77919, Q3AC00, Q4JC10, Q51796, Q54WT4, Q55075, Q57557, Q58947, Q58D56, Q5JGT7, Q6L0E6, Q8PWQ0, Q8RDH4, Q8U374

Diamond homologs: A0M5C6, A0Q1T4, A1VXH9, A2RE30, A2RJQ6, A3CM33, A3DBS5, A4VUC8, A4W0M2, A6TQJ6, A7H1H0, A7I166, A7Z781, A8AWM9, A8EV83, A8F478, A8FJQ1, A8MHK8, A8Z631, A8Z6G0, A9KMF5, B0K414, B0KAB8, B0S3Z4, B1HVB2, B1IBL9, B1YJR9, B2A6B7, B2GGD9, B2IQ29, B2USD4, B3PMC1, B4U3Q7, B5E4J4, B5YEQ1, B5ZA69, B6JKN2, B8CXZ0, B8E0B2, B8FM68

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

65 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	49
Likely benign	1
Benign	3

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
155143	GRCh38/hg38 17p11.2(chr17:16858500-20559337)x1	Pathogenic

SpliceAI

2105 predictions. Top by Δscore:

Variant	Effect	Δscore
17:18088085:AGG:A	donor_gain	1.0000
17:18088086:GG:G	donor_gain	1.0000
17:18088086:GGG:G	donor_gain	1.0000
17:18088086:GGGTG:G	donor_loss	1.0000
17:18088087:G:GT	donor_gain	1.0000
17:18088087:GGTGA:G	donor_loss	1.0000
17:18088088:G:GG	donor_gain	1.0000
17:18088088:GTGA:G	donor_loss	1.0000
17:18088089:T:A	donor_loss	1.0000
17:18093805:T:G	acceptor_gain	1.0000
17:18093811:A:AG	acceptor_gain	1.0000
17:18093812:G:GG	acceptor_gain	1.0000
17:18098268:A:AG	acceptor_gain	1.0000
17:18098269:G:GG	acceptor_gain	1.0000
17:18098360:G:GG	donor_gain	1.0000
17:18099015:A:AG	acceptor_gain	1.0000
17:18099016:G:GG	acceptor_gain	1.0000
17:18099630:CA:C	acceptor_loss	1.0000
17:18099631:A:AC	acceptor_loss	1.0000
17:18099632:G:T	acceptor_loss	1.0000
17:18099632:GGAA:G	acceptor_gain	1.0000
17:18099710:G:GT	donor_gain	1.0000
17:18099711:G:T	donor_gain	1.0000
17:18100432:CAAGG:C	donor_loss	1.0000
17:18100434:AGGTG:A	donor_loss	1.0000
17:18100437:T:G	donor_loss	1.0000
17:18100567:A:AG	acceptor_gain	1.0000
17:18100568:G:GG	acceptor_gain	1.0000
17:18100660:G:GG	donor_gain	1.0000
17:18100687:G:GT	donor_gain	1.0000

AlphaMissense

2365 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:18088086:G:C	K21N	1.000
17:18088086:G:T	K21N	1.000
17:18093816:C:T	T23I	1.000
17:18093824:C:G	H26D	1.000
17:18093837:T:C	L30P	1.000
17:18093842:G:C	A32P	1.000
17:18093849:T:C	L34P	1.000
17:18093861:G:C	R38P	1.000
17:18093911:T:C	F55L	1.000
17:18093913:T:A	F55L	1.000
17:18093913:T:G	F55L	1.000
17:18093953:G:A	G69R	1.000
17:18093953:G:C	G69R	1.000
17:18093954:G:A	G69E	1.000
17:18093968:G:C	G74R	1.000
17:18093969:G:A	G74D	1.000
17:18093971:A:C	K75Q	1.000
17:18093972:A:T	K75M	1.000
17:18098324:T:C	F94L	1.000
17:18098325:T:C	F94S	1.000
17:18098325:T:G	F94C	1.000
17:18098326:C:A	F94L	1.000
17:18098326:C:G	F94L	1.000
17:18098341:T:G	C99W	1.000
17:18099042:T:C	L114P	1.000
17:18099044:G:C	D115H	1.000
17:18099045:A:G	D115G	1.000
17:18099048:T:C	L116P	1.000
17:18099053:G:A	G118R	1.000
17:18099053:G:C	G118R	1.000

dbSNP variants (sampled 300 via entrez): RS1000210526 (17:18105177 G>C), RS1000268454 (17:18098855 C>A), RS1000325226 (17:18092717 T>C), RS1000395212 (17:18094431 C>T), RS1000706461 (17:18106449 G>A), RS1000840361 (17:18089365 C>T), RS1001107885 (17:18090816 G>T), RS1001270265 (17:18091726 C>T), RS1001274133 (17:18088490 G>T), RS1001580384 (17:18101181 C>G), RS1001599269 (17:18104575 G>T), RS1001675008 (17:18095323 T>C), RS1001937548 (17:18103227 G>C), RS1002005408 (17:18096436 C>T), RS1002052549 (17:18103498 GC>G)

Disease associations

OMIM: gene MIM:602986 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST002539_86	Schizophrenia	2.000000e-08
GCST004946_149	Schizophrenia	7.000000e-10
GCST012229_193	Hip index	5.000000e-09
GCST012229_194	Hip index	5.000000e-08
GCST90020024_515	A body shape index	2.000000e-08
GCST90020029_583	Waist circumference adjusted for body mass index	7.000000e-11

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0008039	BMI-adjusted hip circumference
EFO:0007789	BMI-adjusted waist circumference

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
aristolochic acid I	increases expression	1
bisphenol F	affects cotreatment, increases expression	1
2,4,6-tribromophenol	increases expression	1
bisphenol A	decreases expression	1
decabromobiphenyl ether	increases expression	1
beta-lapachone	decreases expression	1
14-deoxy-11,12-didehydroandrographolide	decreases expression	1
abrine	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	increases expression	1
pentabrominated diphenyl ether 100	increases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
Temozolomide	increases expression	1
Air Pollutants, Occupational	affects expression	1
Benzo(a)pyrene	decreases methylation	1
Dexamethasone	increases expression, affects cotreatment	1
Doxorubicin	increases expression	1
Estradiol	decreases expression	1
Indomethacin	affects cotreatment, increases expression	1
Ivermectin	decreases expression	1
Quercetin	decreases expression	1
Ribonucleotides	affects binding	1
Selenium	increases expression	1
Smoke	decreases expression	1
Vitallium	increases expression	1
Vitamin E	increases expression	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1
beta-Naphthoflavone	increases expression	1
Genistein	decreases expression, increases expression	1
Acrylamide	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.